These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26295078)

  • 1. PCSK9 Inhibitors and Cardiovascular Events.
    Sabatine MS; Wasserman SM; Stein EA
    N Engl J Med; 2015 Aug; 373(8):774-5. PubMed ID: 26295078
    [No Abstract]   [Full Text] [Related]  

  • 2. PCSK9 Inhibitors and Cardiovascular Events.
    Goemann IM; Londero TM; Dora JM
    N Engl J Med; 2015 Aug; 373(8):773-4. PubMed ID: 26287856
    [No Abstract]   [Full Text] [Related]  

  • 3. PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
    Mayor S
    BMJ; 2015 Mar; 350():h1508. PubMed ID: 25782694
    [No Abstract]   [Full Text] [Related]  

  • 4. PCSK9 Inhibitors and Cardiovascular Events.
    Auer J; Berent R; Primus C
    N Engl J Med; 2015 Aug; 373(8):773. PubMed ID: 26287855
    [No Abstract]   [Full Text] [Related]  

  • 5. PCSK9 Inhibitors and Cardiovascular Events.
    Robinson JG; Kastelein JJ
    N Engl J Med; 2015 Aug; 373(8):774. PubMed ID: 26287854
    [No Abstract]   [Full Text] [Related]  

  • 6. Lowering LDL cholesterol is good, but how and in whom?
    Stone NJ; Lloyd-Jones DM
    N Engl J Med; 2015 Apr; 372(16):1564-5. PubMed ID: 25773740
    [No Abstract]   [Full Text] [Related]  

  • 7. Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.
    Huynh K
    Nat Rev Cardiol; 2015 May; 12(5):261. PubMed ID: 25824512
    [No Abstract]   [Full Text] [Related]  

  • 8. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
    JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do PCSK9 inhibitors reduce cardiovascular events?
    Kolber MR; Nickonchuk T; Turgeon R
    Can Fam Physician; 2018 Sep; 64(9):669. PubMed ID: 30209099
    [No Abstract]   [Full Text] [Related]  

  • 10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibition: the next statin?
    Vogel RA
    J Am Coll Cardiol; 2012 Jun; 59(25):2354-5. PubMed ID: 22465426
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipid parameters and cardiovascular events in patients taking statins.
    Brook RD; Rubenfire M
    JAMA; 2012 Jul; 308(2):132; author reply 132-3. PubMed ID: 22782403
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipid parameters and cardiovascular events in patients taking statins.
    Martin SS; Jones SR
    JAMA; 2012 Jul; 308(2):131-2; author reply 132-3. PubMed ID: 22782402
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
    Sabatine MS; Giugliano RP; Wiviott SD; Raal FJ; Blom DJ; Robinson J; Ballantyne CM; Somaratne R; Legg J; Wasserman SM; Scott R; Koren MJ; Stein EA;
    N Engl J Med; 2015 Apr; 372(16):1500-9. PubMed ID: 25773607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
    Lüscher TF
    Eur Heart J; 2016 Dec; 37(48):3545-3548. PubMed ID: 28087743
    [No Abstract]   [Full Text] [Related]  

  • 16. Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events.
    Sniderman AD; Thanassoulis G
    Evid Based Med; 2013 Apr; 18(2):73-4. PubMed ID: 22893654
    [No Abstract]   [Full Text] [Related]  

  • 17. New Drugs for Lowering LDL-Cholesterol.
    Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
    Everett BM; Smith RJ; Hiatt WR
    N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
    [No Abstract]   [Full Text] [Related]  

  • 19. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
    Filardi PP; Paolillo S; Trimarco B
    G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.